Jubilant Pharmova gets 6 USFDA observations for its solid dosage manufacturing facility at Roorkee; Stock sheds 2%

3 Aug 2022 , 10:04 AM

Jubilant Pharmova Limited has announced that the United States Food and Drug Administration (USFDA) has recently concluded audit of the Solid Dosage Formulations facility at Roorkee, India of Jubilant Generics which is a subsidiary of its wholly-owned subsidiary Jubilant Pharma Limited.

As per the filing, the USFDA has issued six observations pursuant to the completion of the audit. The company will submit an action plan on the observations and will engage with US FDA for next steps, the company said.

At around 10:07 AM, Jubilant Pharmova was trading at Rs353.15 per share lower by 2.19% as against previous closing of Rs361.05 pershare on the BSE